Skip to main content

Table 1 Patient characteristics (n = 528)

From: Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment

  ≤65 years (n = 116) 66-70 years (n = 144) 71-75 years (n = 158) >75 years (n = 110) significant difference
patient age, years
mean ± SD; median
62 ± 4; 63 68 ± 2; 68 73 ± 2; 73 78 ± 2; 77 all comparisons (p < 0.01)
prostate volume, cc
mean ± SD; median
42 ± 20; 35 44 ± 20; 39 45 ± 23; 40 46 ± 21; 42 -
PSA<10 ng/mL,
n (%)
66 (57) 93 (65) 95 (60) 55 (50) 66-70 vs. >75 years (p < 0.05)
biopsy Gleason score <7; n (%) 72 (62) 90 (63) 98 (62) 55 (50) 66-70 vs. >75 years (p < 0.05)
prior hormonal therapy; n (%) 46 (40) 50 (35) 55 (35) 41 (37) -
comorbidities;
n (%)
56 (48) 95 (66) 108 (68) 69 (63) ≤65 vs. 66-70/71-75/>75 years (p < 0.05)
hypertension;
n (%)
24 (21) 44 (31) 53 (34) 27 (25) ≤65 vs. 71-75 years (p < 0.05)
coronary heart disease;
n (%)
17 (15) 29 (20) 43 (27) 30 (27) ≤65 vs. 71-75/>75 years (p < 0.05)
diabetes;
n (%)
13 (11) 16 (11) 17 (11) 16 (15) -
COPD;
n (%)
7 (6) 13 (9) 17 (11) 12 (11) -
CCI<5/5/>5;
n (%)
86/17/13 (74/15/11) 69/49/26
(48/34/18)
0/85/73
(0/54/46)
0/47/63
(0/43/57)
for all (p < 0.01), with exception 71-75 vs. >75
  1. SD: standard deviation; PSA: prostate specific antigen; COPD: chronic obstructive pulmonary disease; CCI: Charlson Comotbidity Index